Long‐Term Responders After Brentuximab Vedotin: Single‐Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. (2nd August 2016)

• Record Type: Journal Article
• Authors: Gandolfi, Letizia; Pellegrini, Cinzia; Casadei, Beatrice; Stefoni, Vittorio; Broccoli, Alessandro; Tonialini, Lorenzo; Morigi, Alice; Argnani, Lisa; Zinzani, Pier Luigi
• Is Part Of: Oncologist. Volume 21:Number 12(2016)
• Page Start: 1436
• Page End: 1441
• Publication Date: 2016-08-02
• Subjects: Brentuximab vedotin -- Long‐term response -- Real life -- Hodgkin lymphoma -- Systemic anaplastic large cell lymphoma; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2016-0112
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Background: Brentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) with reported long‐term response duration in clinical trials, but few data are available regarding its role in long‐term outcomes in real life. Patients and Methods: A single‐center observational study was conducted on patients treated with BV in daily clinical practice to evaluate the long‐term effectiveness of BV in HL and sALCL patients and to check whether clinical trial results are confirmed in a real‐life context. Results: The best response rate in the treated 53 patients (43 HL and 10 sALCL) was 69.8% (with 46.5% complete response [CR]) in HL and 100% (80% CR) for sALCL, respectively. With a median patient follow‐up of 36.8 months, the estimated median duration of response was 31.5 months for HL and 17.8 for sALCL, respectively. At the latest available follow‐up, 75% of patients were still in response, with 43% without any consolidation. Toxicity was primarily neurological and it was rarely so serious to require dose reduction or interruption. In addition, it always reversed completely after the end of treatment. Conclusion: Our data showed that 51% of patients treated with BV can be regarded as "long‐term responders." Among these cases, for all patients who underwent stem cell transplantation immediately after BV, the procedure was consolidative. For patients who have remained in continuous CR without any consolidation after therapy, BV can induce prolonged disease control. Implications for Practice: Brentuximab vedotin (BV) has shown a high overall response rate in refractory/relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, with reported long‐term response duration in clinical trials, whereas few data are available regarding its role in long‐term outcomes in real life. The data reported in this study suggest that BV can induce the same results in daily clinical practice. The data showed that 51% of patients treated with BV can be regarded as "long‐term responders." Among these cases, BV can induce prolonged disease control in patients who have remained in continuous complete response without any consolidation after the drug. Abstract : Brentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma with reported long‐term response duration in clinical trials, but few data are available regarding its role in long‐term outcomes in real life. This single‐center observational study produced data showing that 51% of patients treated with BV can be regarded as "long‐term responders." Among these cases, for all patients who underwent stem cell transplantation immediately after BV, the procedure was consolidative. For patients who have remained in continuous complete response without any consolidation after therapy, BV can induce prolonged disease control.